Skip to main content

Table 2 Comparison of the baseline parameters in the subgroups of ACR30 responders and non-responders after 12 weeks of treatment

From: Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

  ETA + MTX, week 12 ACR30 responders (n = 33) Placebo + MTX, week 12 ACR30 responders (n = 20) Placebo + MTX, week 12 ACR30 non-responders (n = 12) p
Number of joints with LOM 8 (5–17) 6 (4–7.5) 5 (3.5–10.5) 0.030
Tender joint count 10 (5–19) 6 (4–8) 6 (3.5–10.5) 0.023
VAS disease Activity (physician’s) 8 (6–9) 6 (6–7) 6.5 (4.5–8) 0.036
JADAS-71 24 (19–34) 19.3 (19–23.8) 17 (14–27) 0.020
CRP level 3.6 (1–26) 1.6 (0.7–9.4) 1.1 (0.1–2.9) 0.031
  1. Comparison of the baseline parameters of the different treatment regimens: the standard scheme including the consequent addition of ETA to non-responders to MTX monotherapy vs the scheme with ETA + MTX combination therapy received over 12 weeks
  2. P values are based on the non-parametric Kruskal–Wallis test by rank and median multiple comparisons